Colon Cancer
Colon Cancer News and Colon Cancer Information.

Cancer center honors Robin Roberts with award - Newsday
BUFFALO, N.Y. - Robin Roberts , co-anchor of ABC’s Good Morning America and a breast cancer survivor, is this year’s recipient of the Roswell Park Cancer Institute’s Gilda Radner Courage Award. Named for the late comedian, the award recognizes cancer

PhytoMedical’s In Vivo Toxicity and Efficacy Tests on Human Colon - MSN MoneyCentral
PhytoMedical Technologies, Inc. PYTO (FWB: ET6), today announced the results of its anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. I am encouraged by the results of our human colon

Cancer-Stricken Man Sentenced to Life in Prison - KTVN.com
A cancer-stricken man with only a few months to live has been sentenced to life in prison for sexually assaulting a young relative in the 1980s. Richard Byrum will be eligible for parole in five years under Thursday’s sentence handed down by Washoe

Novel Marker Of Colon Cancer - Science Daily
ScienceDaily (Oct. 27, 2008) Colon cancer ranks second of all gastrointestinal malignant tumors, it is one of the leading causes of cancer-related deaths worldwide. Until now, several molecules have been reported to play an important role in

Researchers find DNA link between colon cancer, obesity - Arlington Heights Daily Herald
People with a common genetic variation in their fat cells may have some protection against developing colon cancer, according to a study that provides the first DNA link between the deadly tumors and obesity. Fat cells produce adiponectin, a hormone

Erbitux Less Effective For Colon Cancer Patients With Second Gene - Eflux Media
Treatment with cetuximab (Erbitux) was less effective for patients with advanced colorectal cancer with a certain gene mutation, a new study found. Scientists already knew that the presence of K-ras mutations explains about 30 to 40 percent of cases

Colon Cancer Drug Won’t Help Those With Certain Gene Mutation - National Womens Health Information Center
WEDNESDAY, Oct. 22 (HealthDay News) — A new study suggests that people with advanced colon cancer who have a particular gene mutation won’t benefit from the medication cetuximab (Erbitux). While the drug can add months to the lives of people without

Cancer center honors TV anchor Robin Roberts - Forbes
Robin Roberts has been honored in New York for sharing her cancer treatment experience with millions of television viewers. ABC’s “Good Morning America” co-anchor accepted the 2008 Roswell Park Cancer Institute’s Gilda Radner Courage Award on

Beating the odds against cancer - Saratogian
Karen Bjornland Desjardins poses as Miss December in The Colon Club s 2009 Colondar, a calendar designed to educate people about colorectal cancer. Sales of the 2009 Colondar will help The Colon Club continue to produce more projects to raise

Baby saves mum before she leaves the womb - News.com.au
ANNALEENA Daley may have saved her mother’s Penny’s life - even before she left the womb, when doctors detected bowel cancer. She was born by caesarean section at only 29 weeks’ gestation, a month after her mother Penny, 28, was diagnosed with the

GenoMed Launches War on Cancer - Phramalive.com
ST. LOUIS, Oct. 29, 2008 GenoMed (OTC Pink Sheets GMED.PK), a Next Generation Disease Management company, announced the opening of its campaign against cancer today. As befits the pioneer company in preventive molecular medicine, GenoMed can

Biotech Stock-Picking: Incyte, Celgene - Street.Com
TheStreet.com’s Adam Feuerstein says, “Biotechnology is one of the few investment sectors where stocks can literally double overnight.” So how much do you know about investing in biotech stocks ? Get up to speed with the following insights and advice

Scantastic ways to discover what health risks you face - Daily Mail
Scans are now one of the most common tools used by doctors and can pick up early warning signs of hundreds of conditions from heart attack and stroke to hepatitis. And although they are used by the NHS, we increasingly take our health into our own

UIC researchers developing new drug class to combat Alzheimer’s - RxPG
By University of Illinois at Chicago, [RxPG] The University of Illinois at Chicago College of Pharmacy has received a four-year, $1.87 million grant from the National Institutes of Health to continue research into discovering a new drug class that

Maui cancer-treatment access to improve - Honolulu Advertiser
WAILUKU, Maui When Robyn Crozier was diagnosed with colon cancer four years ago, she wanted “to fight it with everything I got.” The 44-year-old mother of three said she didn’t hesitate to sign up for a clinical trial of new drug treatment

Study Published in New England Journal of Medicine Shows K-ras Gene - MSN MoneyCentral
ImClone Systems Incorporated IMCL and Bristol-Myers Squibb Company BMY today announced the publication of study results showing that metastatic colorectal cancer (mCRC) patients with wild-type or normal K-ras tumors who were treated with

For cancer patients, personalized treatment offers a new range of - Los Angeles Times
The one thing Kevin Carlberg refused to face after his diagnosis with brain cancer in 2002 was anyone’s estimate for how long he might live. His doctors and his family all knew the number: six to 18 months. “I understand the averages,” says Carlberg

Lessons about Cancer - KSDK
KUSA — Mrs. Jewely Del Duca is the teacher of this class. She is 35 years old and battling stage 4 colon cancer. Jewely learned of the diagnosis several months ago. It took doctors two surgeries, a blood test, a colonoscopy and a cat scan to make

Maui cancer-treatment access to improve - Honolulu Advertiser
WAILUKU, Maui When Robyn Crozier was diagnosed with colon cancer four years ago, she wanted “to fight it with everything I got.” The 44-year-old mother of three said she didn’t hesitate to sign up for a clinical trial of new drug treatment

Tests Could Predict Benefit From Cancer Drugs - Forbes
WEDNESDAY, Oct. 29 (HealthDay News) — What if a blood test or biopsy could predict if a cancer therapy will help cure you, or only make you feel worse? Tests like these, based on genes, proteins or other “molecular markers” may someday do just that

Erbitux Less Effective For Colon Cancer Patients With Second Gene - Eflux Media
Treatment with cetuximab (Erbitux) was less effective for patients with advanced colorectal cancer with a certain gene mutation, a new study found. Scientists already knew that the presence of K-ras mutations explains about 30 to 40 percent of cases

Maui cancer-trial access to improve - Honolulu Advertiser
WAILUKU, Maui When Robyn Crozier was diagnosed with colon cancer four years ago, she wanted “to fight it with everything I got.” The 44-year-old mother of three said she didn’t hesitate to sign up for a clinical trial of a new drug treatment

For cancer patients, personalized treatment offers a new range of - Los Angeles Times
The one thing Kevin Carlberg refused to face after his diagnosis with brain cancer in 2002 was anyone’s estimate for how long he might live. His doctors and his family all knew the number: six to 18 months. “I understand the averages,” says Carlberg

Erbitux Less Effective For Colon Cancer Patients With Second Gene - Eflux Media
Treatment with cetuximab (Erbitux) was less effective for patients with advanced colorectal cancer with a certain gene mutation, a new study found. Scientists already knew that the presence of K-ras mutations explains about 30 to 40 percent of cases

Study Published in New England Journal of Medicine Shows K-ras Gene - MSN MoneyCentral
ImClone Systems Incorporated IMCL and Bristol-Myers Squibb Company BMY today announced the publication of study results showing that metastatic colorectal cancer (mCRC) patients with wild-type or normal K-ras tumors who were treated with

Maui cancer-treatment access to improve - Honolulu Advertiser
WAILUKU, Maui When Robyn Crozier was diagnosed with colon cancer four years ago, she wanted “to fight it with everything I got.” The 44-year-old mother of three said she didn’t hesitate to sign up for a clinical trial of new drug treatment

For cancer patients, personalized treatment offers a new range of - Los Angeles Times
The one thing Kevin Carlberg refused to face after his diagnosis with brain cancer in 2002 was anyone’s estimate for how long he might live. His doctors and his family all knew the number: six to 18 months. “I understand the averages,” says Carlberg

Scientists Find Second Gene That Foils ImClone Drug (Update1) - Bloomberg
Oct. 23 (Bloomberg) — ImClone Systems Inc. and Merck KGaA’s Erbitux, which doesn’t work for advanced colorectal cancer patients with a certain gene mutation, is also futile in people with a second, unrelated aberration, a study found. Patients with

Genentech continues early-stage colon cancer study - KTVN.com
SOUTH SAN FRANCISCO, Calif. (AP) - Biotechnology company Genentech Inc. said Monday a late-stage study of Avastin focusing on early-stage colon cancer will continue, following an independent safety analysis. The current study, being conducted by the

Genentech to continue Phase III colon cancer study - Pharmaceutical Business Review
The National Surgical Adjuvant Breast and Bowel Project’s (NSABP) decision to continue the trial was based on a recommendation from an independent data monitoring committee (DMC) after a planned interim analysis. The study of 2,710 patients is being

Genentech Continues Avastin Colon Study - eNews 2.0
The leading biotechnology company Genentech Inc. said a Phase III study of its drug Avastin focusing on early-stage colon cancer will not be discontinued. The 2,710-patient clinical study, which is carried out by the National Surgical Adjuvant Breast

Colon Cancer Drug Won’t Help Those With Certain Gene Mutation - WAFF
WEDNESDAY, Oct. 22 (HealthDay News) — A new study suggests that people with advanced colon cancer who have a particular gene mutation won’t benefit from the medication cetuximab (Erbitux). While the drug can add months to the lives of people without

Task force: Colon screenings can stop at 75 - Daily Local News
Most people over 75 should stop getting routine colon cancer tests, according to a government health task force that also rejected the latest X-ray screening technology. The U.S. Preventive Services Task Force in a break with other medical and

Cancer center honors TV anchor Robin Roberts - NWITimes.com
BUFFALO, N.Y. - Robin Roberts has been honored in New York for sharing her cancer treatment experience with millions of television viewers. ABC’s “Good Morning America” co-anchor accepted the 2008 Roswell Park Cancer Institute’s Gilda Radner Courage

Genentech Continues Avastin Colon Study - eNews 2.0
The leading biotechnology company Genentech Inc. said a Phase III study of its drug Avastin focusing on early-stage colon cancer will not be discontinued. The 2,710-patient clinical study, which is carried out by the National Surgical Adjuvant Breast

Genentech continues study of Avastin for early-stage colon cancer - Santa Cruz Sentinel
Biotechnology company Genentech said today it will continue a late-stage study of Avastin focusing on early-stage colon cancer, following an independent safety analysis. The current study involves an Avastin treatment combination with the

Genentech to continue with late-stage study of drug Avastin for early - KTVN.com
SOUTH SAN FRANCISCO, Calif. (AP) - Biotechnology company Genentech Inc. says it will continue with a late-stage study of its drug Avastin for early-stage colon cancer. The announcement today comes after an independent safety analysis of the drug

Key Study Of Genentech’s Avastin Ongoing After Interim Peek - Wall Street Journal
NEW YORK (Dow Jones)–Genentech Inc. (DNA) will continue a key study of blockbuster cancer treatment Avastin in treating early colon cancer, after a third-party interim analysis. The move shouldn’t affect or be considered an indication of the study’s

Genentech Continues Avastin Colon Study - eNews 2.0
The leading biotechnology company Genentech Inc. said a Phase III study of its drug Avastin focusing on early-stage colon cancer will not be discontinued. The 2,710-patient clinical study, which is carried out by the National Surgical Adjuvant Breast

Genentech continues study of Avastin for early-stage colon cancer - Silicon Valley
Biotechnology company Genentech said today it will continue a late-stage study of Avastin focusing on early-stage colon cancer, following an independent safety analysis. The current study involves an Avastin treatment combination with the

Genentech continues early-stage colon cancer study - San Francisco Gate
Biotechnology company Genentech Inc. said Monday it will continue a late-stage study of Avastin focusing on early-stage colon cancer, following an independent safety analysis. The current study involves an Avastin treatment combination with the

Key Study Of Genentech’s Avastin Ongoing After Interim Peek - Wall Street Journal
NEW YORK (Dow Jones)–Genentech Inc. (DNA) will continue a key study of blockbuster cancer treatment Avastin in treating early colon cancer, after a third-party interim analysis. The move shouldn’t affect or be considered an indication of the study’s

Genentech Announces Phase III Study of Avastin Plus Chemotherapy in - MSN MoneyCentral
Genentech, Inc. DNA today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin (bevacizumab) plus chemotherapy in patients with early-stage

NY cancer center honors ‘Good Morning America’ co-anchor Robin Roberts - Grand Forks Herald
BUFFALO, N.Y. Robin Roberts has been honored in New York for sharing her cancer treatment experience with millions of television viewers. ABC’s “Good Morning America” co-anchor accepted the 2008 Roswell Park Cancer Institute’s Gilda Radner Courage

Cancer center honors TV anchor Robin Roberts - Forbes
Robin Roberts has been honored in New York for sharing her cancer treatment experience with millions of television viewers. ABC’s “Good Morning America” co-anchor accepted the 2008 Roswell Park Cancer Institute’s Gilda Radner Courage Award on

Study Published in New England Journal of Medicine Shows K-ras Gene - MSN MoneyCentral
ImClone Systems Incorporated IMCL and Bristol-Myers Squibb Company BMY today announced the publication of study results showing that metastatic colorectal cancer (mCRC) patients with wild-type or normal K-ras tumors who were treated with

Genentech continues study of Avastin for early-stage colon cancer - Silicon Valley
Biotechnology company Genentech said today it will continue a late-stage study of Avastin focusing on early-stage colon cancer, following an independent safety analysis. The current study involves an Avastin treatment combination with the